Recent advances in drug design of epidermal growth factor receptor inhibitors

Current Medicinal Chemistry

Volumn 20, Issue 16, 2013, Pages 2043-2067

  Warnault, P ^a,b   Yasri, A ^b   Coisy Quivy, M ^b   Cheve G ^b   Bories C ^b   Fauvel, B ^b   Benhida, R ^a  

^a UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS   (France)

^b OriBase Pharma   (France)

Author keywords

Breast cancer; Drug design; EGFR; Irreversible inhibitors; Mutation; NSCLC; Reversible inhibitors

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFATINIB; BMS 690514; BPI 2009H; CANERTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXEL 7647; GEFITINIB; HM 78136B; ICOTINIB; LAPATINIB; MP 412; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; NERATINIB; PELITINIB; PEMETREXED; UNCLASSIFIED DRUG; VANDETANIB;

ACNE; ADVANCED CANCER; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CHEMICAL STRUCTURE; CRYSTALLOGRAPHY; DIARRHEA; DRUG BINDING; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENE DELETION; GENE MUTATION; HUMAN; IC 50; LEUKOCYTE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; MOUTH ULCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BREAST; BREAST NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84877998630     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320160001     Document Type: Review

References (143)

1. Citri, A.; Yarden, Y. EGF-ErbB signalling: Towards the systems level. Nat. Rev. Mol. Cell. Biol., 2006, 7, 505-516. (Pubitemid 44036456)
2. Holbro, T.; Hynes, N. E. ErbB Receptors: Directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 195-217. (Pubitemid 38263839)
3. Burden, S.; Yarden, Y. Neuregulins and their receptors: A versatile signalling module in organogenesis and oncogenesis. Neuron., 1997, 18, 847-855. (Pubitemid 27274603)
4. Hynes, N. E.; MacDonald, G. ErbB Receptors and signaling pathways in cancer. Curr. Opin. Cell. Biol., 2009, 21, 177-184.
5. Stella, G. M.; Luisetti, M.; Inghilleri, S.; Cemmi, F.; Scabini, R.; Zorzetto, M.; Pozzi, E. Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies. Respir. Med., 2012, 106, 173-183.
6. Sequist, L. V.; Lynch, T. J. EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Ann. Rev. Med., 2008, 59, 429-442. (Pubitemid 351287947)
7. Akhdar, A.; Bronsard, M.; Lemieux, R.; Geha.; S. HER-2 Oncogene amplification assessment in invasive breast cancer by dualcolor in situ hybridization (dc-CISH): A comparative study with fluorescent in situ hybridization (FISH). Ann. Pathol., 2011, 31, 472-479.
8. Duchnowska, R.; Biernat, W.; Szostakiewicz, B.; Sperinde, J.; Piette, F.; Haddad, M.; Paquet, A.; Lie, Y.; Czartoryska-Arukowicz, B.; Wysocki, P.; Jankowski, T.; Radecka, B.; Foszczynska-Koda, M.; Litwiniuk, M.; Debska, S.; Weidler, J.; Huang, W.; Buyse, M.; Bates, M.; Jassem, J. Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy. Oncologist, 2012; 17, 26-35
9. Endres, N. F.; Engel. K.; Das, R.; Kovacs, E.; Kuriyan, J. Regulation of the catalytic activity of the EGF receptor. Curr. Opin. Struct. Biol., 2011, 21, 1-8.
10. Natoli, C.; Perrucci, B.; Perrotti, F.; Falchi, L.; Iacobelli, S. Tyrosine kinase inhibitors. Curr. Cancer Drug Targets, 2010, 10, 462-483.
11. Chou, T. Y.; Chiu, C. H.; Li, L. H.; Hsiao, C. Y.; Tzen, C. Y.; Chang, K. T.; Chen, Y. M.; Perng, R. P.; Tsai, S. F.; Tsai, C. M. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res., 2005, 11, 750-757.
12. Jänne, P. A.; Engelman, J. A.; Johnson, B. E.; Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J. Clin. Oncol., 2005, 23, 3227-3234. (Pubitemid 46211347)
13. Ou, S. H. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Crit. Rev. Oncol. Hematol., 2012.
14. Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett., 2001, 11, 1911-1914. (Pubitemid 32675316)
15. Shepherd, F. A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 2005, 353, 123-132. (Pubitemid 41058344)
16. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J.G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350, 2129-2139. (Pubitemid 38637993)
17. Engelman, J. A.; Jänne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin. Cancer Res., 2008, 14, 2895-2899.
18. Vikis, H.; Sato, M.; James, M.; Wang, D.; Wang, Y.; Wang, M.; Jia, D.; Liu, Y.; Bailey-Wilson, J. E.; Amos, C. I.; Pinney, S. M.; Petersen, G. M.; de Andrade, M.; Yang, P.; Wiest, J. S.; Fain, P. R.; Schwartz, A. G.; Gazdar, A.; Gaba, C.; Rothschild, H.; Mandal, D.; Kupert, E.; Seminara, D.; Viswanathan, A.; Govindan, R.; Minna, J.; Anderson, M. W.; You, M. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res., 2007, 67, f4665-f4670.
19. Pallis, A.; Briasoulis, E.; Linardou, H.; Papadimitriou, C.; Bafaloukos, D.; Kosmidis, P.; Murray, S. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: Clinical and molecular considerations. Curr. Med. Chem., 2011, 18, 1613-1628.
20. Stamos, J.; Sliwkowski, M.X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem., 2002, 277, 46265-46272. (Pubitemid 35417619)
21. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res., 2004, 64, 6652-6659. (Pubitemid 39297926)
22. Niculescu-Duvaz, D.; Whittaker, S.; Springer, C.; Marais, R. The EGF receptor Hokey-Cokey. Cancer Cell., 2007, 11, 209-211. (Pubitemid 46349847)
23. Paez, J. G.; Jänne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 2004, 304, 1497-1500. (Pubitemid 38720929)
24. Langer, C. J. Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges. Crit. Rev. Oncol. Hematol., 2012, 83, 133-144.
25. Gazdar, A. F.; Thun, M. J. Lung cancer, smoke exposure, and sex. J. Clin. Oncol., 2007, 25, 469-471. (Pubitemid 350002950)
26. Chan, S. K.; Gullick, W. J.; Hill, M. E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -search and destroy. Eur. J. Cancer, 2006, 42, 17-23. (Pubitemid 41814528)
27. Shigematsu, H.; Gazdar, A. F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer, 2006, 118, 57-62.
28. Yun, C. H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J.; Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell., 2007, 11, 217-227. (Pubitemid 46349842)
29. Sawyers, C. L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev., 2003, 17, 2998-3010. (Pubitemid 38040763)
30. Bean, J.; Brennan, C.; Shih, J. Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.C.; Yu, C. J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S. F.; Yang, P. C.; Miller, V.; Ladanyi, M., Yang, C. H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA., 2007, 104, 20932-20937.
31. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2005, 2, 73.
32. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Jänne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2005, 352, 786-792. (Pubitemid 40271173)
33. Kosaka, T.; Yatabe, Y.; Endoh, H.; Yoshida, K.; Hida, T.; Tsuboi, M.; Tada, H.; Kuwano, H.; Mitsudomi, T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res., 2006, 12, 5764-5769. (Pubitemid 44629607)
34. Description of iressa, gefinib tablets: Http://www.accessdata.fda.gov/ drugsatfda-docs/label/2003/021399lbl.pdf (Accessed April, 21, 2012)
35. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, An irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27, 4702-4711.
36. Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; Gibson, K. H. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res., 2002, 62, 5749-5754. (Pubitemid 35204731)
37. Herbst, R. S.; Maddox, A. M.; Rothenberg, M. L.; Small, E. J.; Rubin, E. H.; Baselga, J.; Rojo, F.; Hong, W. K.; Swaisland, H.; Averbuch, S. D.; Ochs, J.; LoRusso, P. M. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J. Clin. Oncol., 2002, 20, 3815-3825.
38. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol., 2003, 21, 2237-2246. (Pubitemid 46621858)
39. Food and drug administration. Gefitinib information. http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInfor mationforPatientsandProviders/ ucm110473.htm. (Accessed April 21, 2012)
40. Kris, M. G.; Natale, R. B.; Herbst, R.S.; Lynch, T.J. Jr.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J.; Kay, A. C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA, 2003, 290, 2149-2158. (Pubitemid 37432975)
41. Paez, J. G.; Jänne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 2004, 304, 1497-1500. (Pubitemid 38720929)
42. Naumov, G. N.; Nilsson, M. B.; Cascone, T.; Briggs, A.; Straume, O.; Akslen, L.A.; Lifshits, E.; Byers, L. A.; Xu, L.; Wu, H. K.; Jänne, P.; Kobayashi, S.; Halmos, B.; Tenen, D.; Tang, X. M.; Engelman, J.; Yeap, B.; Folkman, J.; Johnson, B. E.; Heymach, J. V. Combined VEGFR and EGFR blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res., 2009, 15, 3484-3494.
43. Kosaka, T.; Yatabe, Y.; Endoh, H.; Yoshida, K.; Hida, T.; Tsuboi, M.; Tada, H.; Kuwano, H.; Mitsudomi, T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res., 2006, 12, 5764-5769. (Pubitemid 44629607)
44. Kuang, Y.; Rogers, A.; Yeap, B. Y.; Wang, L.; Makrigiorgos, M.; Vetrand, K.; Thiede, S.; Distel, R. J.; Jänne, P. A. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res., 2009, 15, 2630-2636.
45. Watanabe, S.; Tanaka, J.; Ota, T.; Kondo, R.; Tanaka, H.; Kagamu, H.; Ichikawa, K.; Koshio, J.; Baba, J.; Miyabayashi, T.; Narita, I.; Yoshizawa, H. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: A retrospective analysis. BMC Cancer, 2011, 11, 1.
46. Sequist, L. V.; Waltman, B. A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A. B.; Fidias, P.; Bergethon, K.; Shaw, A. T.; Gettinger, S.; Cosper; A. K.; Akhavanfard, S.; Heist, R. S.; Temel, J.; Christensen, J. G.; Wain, J. C.; Lynch, T. J.; Vernovsky, K.; Mark, E. J.; Lanuti, M.; Iafrate, A. J.; Mino-Kenudson, M.; Engelman, J. A. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 2011, 3, 75ra26.
47. Blencke, S.; Ullrich, A.; Daub, H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem., 2003, 278, 15435-15440. (Pubitemid 36799884)
48. Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines. Bioorg. Med. Chem. Lett., 1997, 7, 2723-2728. (Pubitemid 27472818)
49. Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett., 2001, 11, 1911-1914. (Pubitemid 32675316)
50. Pollack, V. A.; Savage, D. M.; Baker, D. A.; Tsaparikos, K. E.; Sloan, D. E.; Moyer, J. D.; Barbacci, E. G.; Pustilnik, L. R.; Smolarek, T. A.; Davis, J. A.; Vaidya, M. P.; Arnold, L. D.; Doty, J. L.; Iwata, K. K.; Morin, M. J. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther., 1999, 291, 739-748. (Pubitemid 29503548)
51. Hidalgo, M.; Siu, L. L.; Nemunaitis, J.; Rizzo, J.; Hammond, L. A.; Takimoto, C.; Eckhardt, S. G.; Tolcher, A.; Britten, C. D.; Denis, L.; Ferrante, K.; Von Hoff, D. D.; Silberman, S.; Rowinsky, E. K. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol., 2001, 19, 3267-3279. (Pubitemid 32591445)
52. Tsao, M. S.; Sakurada, A.; Cutz, J. C.; Zhu, C. Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F. A. Erlotinib in lung cancer -molecular and clinical predictors of outcome. N. Engl. J. Med., 2005, 353, 133-144. (Pubitemid 41058345)
53. Tang, Z.; Du, R.; Jiang, S.; Wu, C.; Barkauskas, D. S.; Richey, J.; Molter, J.; Lam, M.; Flask, C.; Gerson, S.; Dowlati, A.; Liu, L.; Lee, Z.; Halmos, B.; Wang, Y.; Kern, J. A.; Ma, P. C. Dual METEGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br. J. Cancer, 2008, 99, 911-922.
54. Synthesis of erlotinib. http://www.drugfuture.com/synth/syndata. aspx?ID=250837 (Accessed April 22, 2012)
55. Vogel, C.; Chan, A.; Gril, B.; Kim, S. B.; Kurebayashi, J.; Liu, L.; Lu, Y. S.; Moon, H. Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib. Jpn. J. Clin. Oncol., 2010, 40, 999-1013.
56. Food and drug administration. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022059s007lbl.pdf? utm-source=fdaSearch&utm-medium=website &utm-term=lapatinib&utm- content=6. (Access April 22, 2012)
57. Clinical trials. A Phase II trial of Lapatinib. http://clinicaltrials. gov/ct2/show/NCT00528281?term=lapatinib+lu ng+cancer&rank=1 (Access April 22, 2012)
58. Medina, P. J.; Goodin, S. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther., 2008, 30, 1426-1447.
59. Wainberg, Z. A.; Anghel, A.; Desai, A. J.; Ayala, R.; Luo, T.; Safran, B.; Fejzo, M. S.; Hecht, J. R.; Slamon, D. J.; Finn, R. S. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res., 2010, 16, 1509-1519.
60. Bilancia, D.; Rosati, G.; Dinota, A.; Germano, D.; Romano, R.; Manzione, L. Lapatinib in breast cancer. Ann. Oncol., 2007, 6, 26-30.
61. Gilmer, T. M.; Cable, L.; Alligood, K.; Rusnak, D.; Spehar, G.; Gallagher, K. T.; Woldu, E.; Carter, H. L.; Truesdale, A. T.; Shewchuk, L.; Wood, E. R. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res., 2008, 68, 571-579. (Pubitemid 351380086)
62. Jyothi Prasad, R.; Adibhatla Kali Satya, B. R.; Venkaiah Chowdary, N. A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts. W.O. patent 2010/061,400, June 3, 2010.
63. Zhao, Q.; Shentu, J.; Xu, N.; Zhou, J.; Yang, G.; Yao, Y.; Tan, F.; Liu, D.; Wang, Y.; Zhou, J. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer, 2011, 73, 195-202.
64. Drugs approval. Icotinib. http://icotinib-global.com/icotinibnews. html. (Accessed April 22, 2012)
65. Tan, F.; Shen, X.; Wang, D.; Xie, G.; Zhang, X.; Ding, L.; Hu, Y.; He, W.; Wang, Y.; Wang, Y. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 2012, 76, 177-182.
66. Ren, G. J.; Zhao, Y. Y.; Zhu, Y. J.; Xiao, Y.; Xu, J. S.; Shan, B.; Zhang; L. Tumor gene mutations and messenger RNA expression: Correlation with clinical response to icotinib hydrochloride in nonsmall cell lung cancer. Chin. Med. J., 2011 124, 19-25.
67. Zhang, D.; Xie, G.; Davis, C.; Cheng, Z.; Chen, H.; Wang, Y.; Kamal, M. Preparation of novel fused quinazoline derivatives as tyrosine kinase inhibitors. W.O. patent 2003/082,830, October 9, 2003.
68. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D.; Fry, D.W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structureactivity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem., 1996, 39, 267-276.
69. 2011 FDA drug approvals. Nature Reviews Drugs Discovery, 2012, 11, 91-94.
70. Hennequin, L. F.; Stokes, E. S.; Thomas, A. P.; Johnstone, C.; Plé, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O.; Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem., 2002, 45, 1300-1312. (Pubitemid 34263566)
71. Amini, A.; Moghaddam, S. M.; Morris, D. L.; Pourgholami, M.H. The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr. Cancer Drug Targets, 2012, 12, 23-43.
72. Food and drug administration. Memorandum Vendetanib. http://www. accessdata.fda.gov/drugsatfda-docs/nda/2011/022405O rig1s000PharmR.pdf. (Accessed April 22, 2012)
73. Morabito, A.; Piccirillo, M. C.; Falasconi, F.; De Feo, G.; Del Giudice, A.; Bryce, J.; Di Maio, M.; De Maio, E.; Normanno, N.; Perrone, F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future directions. Oncologist, 2009, 14, 378-390.
74. Tamura, T.; Minami, H.; Yamada, Y.; Yamamoto, N.; Shimoyama, T.; Murakami, H.; Horiike, A.; Fujisaka, Y.; Shinkai, T.; Tahara, M.; Kawada, K.; Ebi, H.; Sasaki, Y.; Jiang, H.; Saijo, N. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J. Thorac. Oncol., 2006, 1, 1002-1009. (Pubitemid 47181370)
75. Holden, S. N.; Eckhardt, S. G.; Basser, R.; de Boer, R.; Rischin, D.; Green, M.; Rosenthal, M. A.; Wheeler, C.; Barge, A.; Hurwitz, H. I. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol., 2005, 16, 1391-1397. (Pubitemid 41158486)
76. Hennequin, L. F.; Stokes, E. S.; Thomas, A. P.; Johnstone, C.; Plé, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem., 2002, 45, 1300-1312. (Pubitemid 34263566)
77. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S.; Plé, P. A.; Lohmann, J. J.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R; Curwen, J. O.; Kendrew, J.; Lambert-van der Brempt, C. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem., 1999, 42, 5369-5389. (Pubitemid 30036772)
78. Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G.; AEE788 : A Dual Family Epidermal Growth Factor Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity. Cancer Res., 2004, 64, 4931-4941. (Pubitemid 38924540)
79. De La Motte Rouge, T.; Galluzzi, L.; Olaussen, K. A.; Zermati, Y.; Tasdemir, E.; Robert, T.; Ripoche, H.; Lazar, V.; Dessen, P.; Harper, F.; Pierron, G.; Pinna, G.; Araujo, N.; Harel-Belan, A.; Armand, J.P.; Wong, T. W.; Soria, J. C.; Kroemer, G. A. Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non?Small Cell Lung Cancer Cells Resistant to Erlotinib. Cancer Res., 2007; 67, 6253-6262. (Pubitemid 47037507)
80. Wong, T. W.; Lee, F. Y.; Yu, C.; Luo, F. R.; Oppenheimer, S.; Zhang, H.; Smykla, R. A.; Mastalerz, H.; Fink, B. E.; Hunt, J. T.; Gavai, A. V.; Vite, G. D. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin. Cancer Res., 2006, 12, 6186-6193. (Pubitemid 44703785)
81. Barlaam, B.; Acton, D. G.; Ballard, P.; Bradbury, R. H.; Cross, D.; Ducray, R.; Germain, H.; Hudson, K.; Klinowska, T.; Magnien, F.; Ogilvie, D. J.; Olivier, A.; Ross, H. S.; Smith, R.; Trigwell, C. B.; Vautier, M.; Wright, L. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of ErbB2 receptor tyrosine kinase. Bioorg. Med. Chem. Lett., 2008, 18, 1799-1803. (Pubitemid 351391850)
82. Gendreau, S. B.; Ventura, R.; Keast, P.; Laird, A. D.; Yakes, F. M.; Zhang, W.; Bentzien, F.; Cancilla, B.; Lutman, J.; Chu, F.; Jackman, L.; Shi, Y.; Yu, P.; Wang, J.; Aftab, D. T.; Jaeger, C. T., Meyer, S.M.; De Costa, A.; Engell, K.; Chen, J.; Martini, J.F.; Joly, A. H. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin. Cancer Res., 2007, 13, 3713-3723. (Pubitemid 46955136)
83. Trowe, T.; Boukouvala, S.; Calkins, K.; Cutler, R. E. Jr.; Fong, R.; Funke, R.; Gendreau, S. B.; Kim, Y. D.; Miller, N.; Woolfrey, J. R.; Vysotskaia, V.; Yang, J. P.; Gerritsen, M. E.; Matthews, D. J.; Lamb, P.; Heuer, T.S. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin. Cancer Res., 2008, 14, 2465-2475. (Pubitemid 351551082)
84. Sequist, L. V. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist., 2007, 12, 325-330. (Pubitemid 46556799)
85. Engelman, J. A.; Zejnullahu, K.; Gale, C. M.; Lifshits, E.; Gonzales, A. J.; Shimamura, T.; Zhao, F.; Vincent, P. W.; Naumov, G. N.; Bradner, J. E.; Althaus, I. W.; Gandhi, L.; Shapiro, G. I.; Nelson, J. M.; Heymach, J. V.; Meyerson, M.; Wong, K. K.; Jänne, P. A. PF00299804, an irreversible pan-ErbB inhibitor, is effective in lung cancer models with EGFR and ErbB2 mutations that are resistant to gefitinib. Cancer Res., 2007, 67, 11924-11932.
86. Allen, L. F.; Eiseman, I. A.; Fry, D. W.; Lenehan, P. F. CI-1033, An irreversible pan-ErbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin. Oncol., 2003, 30, 65-78. (Pubitemid 37433398)
87. Calvo, E.; Tolcher, A. W.; Hammond, L. A.; Patnaik, A.; de Bono, J. S.; Eiseman, I. A.; Olson, S. C.; Lenehan, P. F.; McCreery, H.; Lorusso, P.; Rowinsky, E. K. Administration of CI-1033, an irreversible pan-ErbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: A phase I pharmacokinetic and food effect study. Clin. Cancer Res., 2004, 10, 7112-7120. (Pubitemid 39487694)
88. Giaccone, G.; Wang, Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat. Rev., 2011, 37, 456-464.
89. Park, K.; Heo, D. S.; Cho, B.; Kim, D.; Ahn, M.; Lee, S.; Millham, R. D.; Campbell, A.; Zhang, H.; Kim, J. PF-00299804 (PF299) In Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. Proc. Am. Soc. Clin. Oncol. Ann. Meet., Chicago, USA., June 4-8, 2010.
90. Takahashi, T.; Boku, N.; Murakami, H.; Naito, T.; Tsuya, A.; Nakamura, Y.; Ono, A.; Machida, N.; Yamazaki, K.; Watanabe, J.; Ruiz-Garcia, A.; Imai, K.; Ohki, E.; Yamamoto, N. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest. New Drugs, 2012, 30, 2352-2363
91. Bello, C. L.; Labadie, R. R.; Ni, G.; Boutros, T.; McCormick, C.; Ndongo, M. N. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother. Pharmacol., 2012, 69, 991-997.
92. Gonzales, A. J.; Hook, K. E.; Althaus, I. W.; Ellis, P. A.; Trachet, E.; Delaney, A. M.; Harvey, P. J.; Ellis, T. A.; Amato, D. M.; Nelson, J. M.; Fry, D. W.; Zhu, T.; Loi, C. M.; Fakhoury, S. A.; Schlosser, K. M.; Sexton, K. E.; Winters, R. T.; Reed, J. E.; Bridges, A. J.; Lettiere, D. J.; Baker, D. A.; Yang, J.; Lee, H. T., Tecle, H.; Vincent, P. W. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-ErbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther., 2008, 7, 1880-1889.
93. Fakhoury, S. A.; Lee, H. T.; Reed, J. E.; Schlosser, K. M; Sexton, K. E.; Tecle, H.; Winters, T. 4-Phenylamino-quinazolin-6-ylamides. U.S. Patent 0,250,761, November 10, 2005.
94. Yap, T. A.; Vidal, L.; Adam, J.; Stephens, P.; Spicer, J.; Shaw, H.; Ang, J.; Temple, G.; Bell, S.; Shahidi, M.; Uttenreuther-Fischer, M.; Stopfer, P.; Futreal, A.; Calvert, H.; de Bono, J. S.; Plummer, R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol., 2010, 28, 3965-3972.
95. Eskens, F. A.; Mom, C. H.; Planting, A. S.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer, 2008, 98, 80-85.
96. Atagi, S.; Katakami, N.; Hida, T.; Goto, K.; Horai, T.; Inoue, A.; Sarashina, A.; Seki, Y.; Lorence, R.; Shahidi, M.; Yamamoto, N. LUX-Lung 4: A phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib. 14th Biennial World Conference on Lung Cancer, Amesterdam, Netherland, July, 3-7, 2011.
97. Clinical trials. Clinical trials of afatinib http://clinicaltrials.gov/ ct2/results?term=afatinib&phase. (Accessed April 23, 2012)
98. Soyka, R.; Rall, W.; Schnaubelt, J.; Sieger, P.; Kulinna, C. Process for preparing amino crotonyl compounds. U.S. Patent 0,085,495, April 21, 2005.
99. Wissner, A.; Hamann, P. R.; Nilakantan, R.; Greenberger, L. M.; Ye, F.; Rapuano, T. A.; Loganzo, F. Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles. Bioorg. Med. Chem. Lett., 2004, 14, 1411-1416. (Pubitemid 38299420)
100. Yoshimura, N.; Kudoh, S.; Kimura, T.; Mitsuoka, S.; Matsuura, K.; Hirata, K.; Matsui, K.; Negoro, S.; Nakagawa, K.; Fukuoka, M. EKB-569, A new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with nonsmall cell lung cancer with acquired resistance to gefitinib. Lung Cancer, 2006, 51, 363-368. (Pubitemid 43265820)
101. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T.J.; Rabindran, S.K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA, 2005, 102, 7665-7670. (Pubitemid 40741028)
102. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Kinzler, K. W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P.; Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med., 2000, 6, 1024-1028.
103. Erlichman, C.; Hidalgo, M.; Boni, J. P.; Martins, P.; Quinn, S. E.; Zacharchuk, C.; Amorusi, P.; Adjei, A. A.; Rowinsky, E. K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol., 2006, 24, 2252-2260. (Pubitemid 46630654)
104. Folprecht, G.; Tabernero, J.; Köhne, C. H.; Zacharchuk, C.; Paz-Ares, L.; Rojo, F.; Quinn, S.; Casado, E.; Salazar, R.; Abbas, R.; Lejeune, C.; Marimón, I.; Andreu, J.; Ubbelohde, U.; Cortes-Funes, H.; Baselga, J. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. Clin. Cancer Res., 2008, 14, 215-223. (Pubitemid 351377998)
105. Wissner, A.; Overbeek, E.; Reich, M.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Greenberger, L. M.; Tsou, H. R. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem., 2003, 46, 49-63. (Pubitemid 36043786)
106. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.; Wissner, A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res., 2004, 64, 3958-3965. (Pubitemid 38697310)
107. Godin-Heymann, N.; Ulkus, L.; Brannigan, B. W.; McDermott, U.; Lamb, J.; Maheswaran, S.; Settleman, J.; Haber, D. A. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible
108. Shimamura, T.; Ji, H.; Minami, Y.; Thomas, R. K.; Lowell, A. M.; Shah, K.; Greulich, H.; Glatt, K. A.; Meyerson, M.; Shapiro, G. I.; Wong, K. K. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ErbB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ErbB2 inhibitor HKI-272. Cancer Res., 2006, 66, 6487-6491. (Pubitemid 44085601)
109. Clinical trials. A phase III trial of neratinib http://clinicaltrials. gov/show/NCT00878709. (Accessed April 23, 2012)
110. Wong, K. K.; Fracasso, P. M.; Bukowski, R. M.; Lynch, T. J.; Munster, P. N.; Shapiro, G. I.; Jänne, P. A.; Eder, J. P.; Naughton, M. J.; Ellis, M. J.; Jones, S. F.; Mekhail, T.; Zacharchuk, C.; Vermette, J.; Abbas, R.; Quinn, S.; Powell, C.; Burris, H. A. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res., 2009, 15, 2552-2558.
111. Calvo, E.; Tolcher, A. W.; Hammond, L. A. Patnaik, A.; de Bon, J. S.; Eiseman, I. A.; Olson, S. C.; Lenehan, P. F.; McCreery, H.; Lorusso, P.; Rowinsky, E. K. Administration of CI-1033, an irreversible pan-ErbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: A phase I pharmacokinetic and food effect study. Clin. Cancer Res., 2004, 10, 7112-7120. (Pubitemid 39487694)
112. Rinehart, J. J.; Wilding, G.; Willson, J.; Krishnamurthi, S.; Natale, R.; Dasse, K. D.; Olson, S.; Marcy, P.; Lenehan, P.; Chakrabarti, D. A phase I clinical and pharmacokinetic (PK)/food effect study of oral CI-1033, a pan-Erb B tyrosine kinase inhibitor, in patients with advanced solid tumors. Proceedings of the American Society of Clinical Oncology Annual Meeting, Chicago, U.S.A., May 31-June 3, 2003.
113. Nemunaitis, J.; Eiseman, I.; Cunningham, C.; Senzer, N.; Williams, A.; Lenehan, P. F.; Olson, S. C.; Bycott, P.; Schlicht, M.; Zentgraff, R.; Shin, D. M.; Zinner, R. G. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin. Cancer Res., 2005, 11, 3846-3853. (Pubitemid 40685605)
114. Jänne, P. A.; von Pawel, J.; Cohen, R. B.; Crino, L.; Butts, C. A.; Olson, S. S.; Eiseman, I. A.; Chiappori, A. A.; Yeap, B. Y.; Lenehan, P. F.; Dasse, K.; Sheeran, M.; Bonomi, P. D. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ErbB inhibitor, for previously treated advanced non small-cell lung cancer. J. Clin. Oncol., 2007, 25, 3936-3944. (Pubitemid 47477271)
115. Chiappori, A. A.; Ellis, P. M.; Hamm, J. T.; Bitran, J. D.; Eiseman, I.; Lovalvo, J.; Burnett, D.; Olson, S.; Lenehan, P.; Zinner, R. G. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J. Thorac. Oncol., 2006, 1, 1010-1019. (Pubitemid 47181371)
116. Simon, G. R.; Garrett, C. R.; Olson, S. C.; Langevin, M.; Eiseman, I. A.; Mahany, J. J.; Williams, C. C.; Lush, R.; Daud, A.; Munster, P.; Chiappori, A.; Fishman, M.; Bepler, G.; Lenehan, P. F.; Sullivan, D. M. Increased bioavailability of intravenous versus oral CI-1033, a pan-ErbB tyrosine kinase inhibitor: Results of a phase I pharmacokinetic study. Clin. Cancer Res., 2006, 12, 4645-4651. (Pubitemid 44297817)
117. Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Showalter, H. D.; Vincent, P. W.; Elliott, W. L.; Denny, W. A. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline-and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem., 2000, 43, 1380-1397. (Pubitemid 30212579)
118. Discafani, C. M.; Carroll, M. L.; Floyd, M. B. Jr.; Hollander, I. J.; Husain, Z.; Johnson, B. D.; Kitchen, D.; May, M.K.; Malo, M. S.; Minnick, A. A. Jr.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Wissner, A.; Greenberger, L. M. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem. Pharmacol., 1999, 57, 917-925. (Pubitemid 29127105)
119. Kobayashi, S.; Ji, H.; Yuza, Y.; Meyerson, M.; Wong, K. K.; Tenen, D. G.; Halmos, B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res., 2005, 65, 7096-7101. (Pubitemid 41161238)
120. Wissner, A.; Mansour, T.S. The Development of HKI-272 and Related Compounds for the Treatment of Cancer. Arch. Pharm. Chem. Life Sci., 2008, 341, 465-477
121. Suzuki, T.; Fujii, A.; Ohya, J.; Amano, Y.; Kitano, Y.; Abe, D.; Nakamura, H. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Sci., 2007, 98, 1977-1984. (Pubitemid 350002206)
122. Suzuki, T.; Fujii, A.; Ochi, H.; Nakamura, H. Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells. J. Cell Biochem., 2011, 112, 2279-2286.
123. Nam, H. J.; Kim, H. P.; Yoon, Y. K.; Hur, H. S.; Song, S. H.; Kim, M. S.; Lee, G. S.; Han, S. W.; Im, S. A.; Kim, T. Y.; Oh, D. Y.; Bang, Y. J. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett., 2011, 302, 155-165.
124. Cha, M. Y.; Lee, K. O.; Kim, M.; Song, J. Y.; Lee, K. H.; Park, J.; Chae, Y. J.; Kim, Y. H.; Suh, K. H.; Lee, G. S.; Park, S. B.; Kim, M. S. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFRdependent cancer models. Int. J. Cancer, 2012,130, 2445-2454.
125. Yu-Jing, Y. J.; Zhang, C. M.; Liu, Z. P. Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds. Anticancer Agents Med. Chem., 2012, 12, 391-406.
126. Challa, R.; Ahuja, A.; Ali, J.; Khar, R. K. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech., 2005, 6, 329-357.
127. Rezler, E. M.; Khan, D. R.; Lauer-Fields, J.; Cudic, M.; Baronas-Lowell, D.; Fields, G. B. Targeted drug delivery utilizing proteinlike molecular architecture. J. Am. Chem. Soc., 2007, 129, 4961-4972. (Pubitemid 46651374)
128. Allen, T. M.; Cullis, P. R. Drug delivery systems: Entering the mainstream. Science, 2004, 303, 1818-1822. (Pubitemid 38374867)
129. Urbanska, A. M.; Karagiannis, E. D.; Guajardo, G.; Langer, R. S.; Anderson, D. G. Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer. Biomaterials, 2012, 33, 4752-4761.
130. Ghosh, I.; Nau, W. M. The strategic use of supramolecular pK(a) shifts to enhance the bioavailability of drugs. Adv. Drug Deliv. Rev., 2012, 64, 764-783.
131. Brown, S.; Khan, D. R. The treatment of breast cancer using liposome technology. J. Drug Deliv., 2012, doi: 10.1155/2012/212965.
132. Singh, J.; Petter, R. C.; Kluge, A. F. Targeted covalent drugs of the kinase family. Curr. Opin. Chem. Biol., 2010, 14, 475-480.
133. Abdullah, S. E.; Haigentz, M. Jr; Piperdi, B. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemother. Res. Pract., 2012, 35, 1210.
134. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.-Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol., 2003, 21, 2237-2246. (Pubitemid 46621858)
135. Herbst, R. S.; LoRusso, P. M.; Purdom, M.; Ward, D. Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clin. Lung Cancer., 2003, 4, 366-369. (Pubitemid 36798559)
136. Joshi, S. S.; Ortiz, S.; Witherspoon, J. N.; Rademaker, A., West, D. P.; Anderson, R.; Rosenbaum, S. E.; Lacouture, M. E. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer, 2010, 116, 3916-3923.
137. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25, 1960-1966. (Pubitemid 46972777)
138. Rossi, A.; Pasquale, R.; Esposito, C.; Normanno, N. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat. Rev., 2012. doi: 10.1016/j.ctrv.2012.09.001.
139. Baas, J. M.; Krens, L. L.; Guchelaar, H. J.; Ouwerkerk, J.; de Jong, F. A.; Lavrijsen, A. P.; Gelderblom, H. Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treat. Rev., 2012, 38, 505-514.
140. Lin, C. C.; Yang, J. C. Optimal management of patients with nonsmall cell lung cancer and epidermal growth factor receptor mutations. Drugs, 2011, 71, 79-88.
141. Ouwerkerk, J.; Boers-Doets, C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur. J. Oncol. Nurs., 2010, 14, 337-349.
142. Chiappori, A. A.; Ellis, P. M.; Hamm, J. T.; Bitran, J. D.; Eiseman, I.; Lovalvo, J.; Burnett, D.; Olson, S.; Lenehan, P.; Zinner, R.G. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J. Thorac. Oncol., 2006, 1, 1010-1019. (Pubitemid 47181371)
143. Nam, H. J.; Ching, K. A.; Kan, J.; Kim, H. P.; Han, S. W.; Im, S. A.; Kim, T. Y.; Christensen, J. G.; Oh, D. Y.; Bang, Y. J. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol. Cancer Ther., 2012, 11, 439-451.